Cenna Biosciences Inc.
Putting a new spin on amyloid beta target in AD
This article was originally published in Start Up
Cenna Biosciences thinks it has come up with a way to target amyloid beta that will succeed where other companies have failed in Alzheimer’s disease. The San Diego-based start-up has developed technology that creates peptide drug candidates that bind the amyloid precursor protein, to prevent amyloid beta buildup in the first place.
Register for our free email digests: